Angiopoietins

Recent Results in Cancer Research

Volumn 180, Issue , 2010, Pages 3-13

  Reiss, Yvonne ^a  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; GROWTH FACTOR; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; AUTOCRINE EFFECT; CANCER INHIBITION; EMBRYO DEATH; ENDOTHELIUM CELL; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 77953671723     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-78281-0_2     Document Type: Review

References (82)

1. Carmeliet P, Ferreira V, Breier G et al (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439
2. Ferrara N, Carver-Moore K, Chen H et al (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442
3. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676
4. Conway EM, Collen D, Carmeliet P (2001) Molecular mechanisms of blood vessel growth. Cardiovasc Res 49:507-521
5. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674
6. Suri C, McClain J, Thurston G et al (1998) Increased vascularization in mice overexpressing angiopoietin- 1. Science 282:468-471
7. Maisonpierre PC, Suri C, Jones PF et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60
8. Brindle NP, Saharinen P, Alitalo K (2006) Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 98:1014-1023
9. Hanahan D (1997) Signaling vascular morphogenesis and maintenance. Science 277:48-50
10. Davis S, Aldrich TH, Jones PF et al (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161-1169 (Pubitemid 27010100)
11. Valenzuela DM, Griffiths JA, Rojas J et al (1999) Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci U S A 96:1904-1909
12. Sato TN, Tozawa Y, Deutsch U et al (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376:70-74
13. Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K, Breitman ML (1995) Vascularization of the mouse embryo: A study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn 203:80-92
14. Barton WA, Tzvetkova-Robev D, Miranda EP et al (2006) Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex. Nat Struct Mol Biol 13:524-532
15. Fiedler U, Krissl T, Koidl S et al (2003) Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 278:1721-1727
16. Dumont DJ, Gradwohl GJ, Fong GH, Auerbach R, Breitman ML (1993) The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. Oncogene 8:1293-1301
17. Sato TN, Qin Y, Kozak CA, Audus KL (1993) Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci U S A 90:9355-9358
18. Schnurch H, Risau W (1993) Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 119:957-968
19. Partanen J, Armstrong E, Makela TP et al (1992) A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol 12:1698-1707
20. Saharinen P, Kerkela K, Ekman N et al (2005) Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J Cell Biol 169:239-243
21. Jones N, Master Z, Jones J et al (1999) Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem 274:30896-30905
22. Papapetropoulos A, Fulton D, Mahboubi K et al (2000) Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275:9102-9105
23. Audero E, Cascone I, Maniero F et al (2004) Adaptor ShcA protein binds tyrosine kinase Tie2 receptor and regulates migration and sprouting but not survival of endothelial cells. J Biol Chem 279: 13224-13233
24. Hayes AJ, Huang WQ, Mallah J, Yang D, Lippman ME, Li LY (1999) Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary- like tubule formation and survival of endothelial cells. Microvasc Res 58:224-237
25. Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W (1998) Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol 8:529-532
26. Suri C, Jones PF, Patan S et al (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180
27. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG (1997) Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 81:567-574
28. Saharinen P, Eklund L, Miettinen J et al (2008) Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cellmatrix contacts. Nat Cell Biol 10:527-537
29. Fukuhara S, Sako K, Minami T et al (2008) Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin- 1. Nat Cell Biol 10:513-526
30. Reiss Y, Droste J, Heil M et al (2007) Angiopoietin-2 impairs revascularization after limb ischemia. Circ Res 101(1):88-96
31. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG (2005) The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 118:771-780
32. Holash J, Maisonpierre PC, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998
33. Stratmann A, Risau W, Plate KH (1998) Cell typespecific expression of angiopoietin-1 and angiopoietin- 2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153:1459-1466
34. Gale NW, Thurston G, Hackett SF et al (2002) Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3:411-423
35. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
36. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
37. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-248
38. Reiss Y, Machein MR, Plate KH (2005) The role of angiopoietins during angiogenesis in gliomas. Brain Pathol 15:311-317
39. Tait CR, Jones PF (2004) Angiopoietins in tumours: the angiogenic switch. J Pathol 204:1-10
40. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160:985-1000
41. Ward NL, Dumont DJ (2002) The angiopoietins and Tie2/Tek: Adding to the complexity of cardiovascular development. Semin Cell Dev Biol 13:19-27
42. Stoeltzing O, Ahmad SA, Liu W et al (2003) Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 63:3370-3377
43. Hawighorst T, Skobe M, Streit M et al (2002) Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 160:1381-1392
44. Tian S, Hayes AJ, Metheny-Barlow LJ, Li LY (2002) Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1. Br J Cancer 86:645-651
45. Stoeltzing O, Ahmad SA, Liu W et al (2002) Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis. Br J Cancer 87:1182-1187
46. Ahmad SA, Liu W, Jung YD et al (2001) The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 61:1255-1259
47. Yu Q, Stamenkovic I (2001) Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am J Pathol 158:563-570
48. Hayes AJ, Huang WQ, Yu J et al (2000) Expression and function of angiopoietin-1 in breast cancer. Br J Cancer 83:1154-1160
49. Shim WS, Teh M, Bapna A et al (2002) Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp Cell Res 279:299-309
50. Machein MR, Knedla A, Knoth R, Wagner S, Neuschl E, Plate KH (2004) Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol 165:1557-1570
51. Cao Y, Sonveaux P, Liu S et al (2007) Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res 67:3835-3844
52. Zhang L, Yang N, Park JW et al (2003) Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63:3403-3412
53. Hu B, Guo P, Fang Q et al (2003) Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A 100:8904-8909
54. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M (2001) Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 61:2145-2153
55. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR (1999) Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103:341-345 (Pubitemid 29069983)
56. Hashizume H, Baluk P, Morikawa S et al (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363-1380
57. Hegen A, Koidl S, Weindel K, Marme D, Augustin HG, Fiedler U (2004) Expression of angiopoietin- 2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler Thromb Vasc Biol 24:1803-1809
58. Ochiumi T, Tanaka S, Oka S et al (2004) Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int J Oncol 24:539-547
59. Sfiligoi C, de Luca A, Cascone I et al (2003) Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 103:466-474
60. Siemeister G, Schirner M, Weindel K et al (1999) Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 59:3185-3191
61. Lin P, Buxton JA, Acheson A et al (1998) Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A 95:8829-8834
62. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K (1997) Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 100:2072-2078
63. Oliner J, Min H, Leal J et al (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6:507-516
64. McDonald DM, Thurston G, Baluk P (1999) Endothelial gaps as sites for plasma leakage in inflammation. Microcirculation 6:7-22
65. Gamble JR, Drew J, Trezise L et al (2000) Angiopoietin-1 is an antipermeability and antiinflammatory agent in vitro and targets cell junctions. Circ Res 87:603-607
66. Wang Y, Pampou S, Fujikawa K, Varticovski L (2004) Opposing effect of angiopoietin-1 on VEGF-mediated disruption of endothelial cellcell interactions requires activation of PKC beta. J Cell Physiol 198:53-61
67. Gavard J, Patel V, Gutkind JS (2008) Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 14:25-36
68. Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8:618-631
69. Grunewald M, Avraham I, Dor Y et al (2006) VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cell 124:175-189
70. De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE (2007) Tie2-expressing monocytes: Regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 28:519-524
71. De Palma M, Venneri MA, Roca C, Naldini L (2003) Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9: 789-795
72. De Palma M, Venneri MA, Galli R et al (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8: 211-226
73. Machein MR, Renninger S, de Lima-Hahn E, Plate KH (2003) Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 13:582-597
74. Fiedler U, Reiss Y, Scharpfenecker M et al (2006) Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12:235-239
75. Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563
76. De Palma M, Mazzieri R, Politi LS et al (2008) Tumor-targeted interferon-alpha delivery by Tie2- expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14:299-311
77. Thurston G, Suri C, Smith K et al (1999) Leakageresistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286: 2511-2514
78. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J (1995) The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 14:5884-5891
79. Puri MC, Partanen J, Rossant J, Bernstein A (1999) Interaction of the TEK and TIE receptor tyrosine kinases during cardiovascular development. Development 126:4569-4580
80. Dumont DJ, Gradwohl G, Fong GH et al (1994) Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8:1897-1909
81. Puri MC, Bernstein A (2003) Requirement for the TIE family of receptor tyrosine kinases in adult but not fetal hematopoiesis. Proc Natl Acad Sci U S A 100:12753-12758
82. Reiss Y, Knedla A, Tal AO et al (2009) Switching of vascular phenotypes within a murine breast cancer model induced by Angiopoietin-2. J Path 217 (4):571-580